Hyperbaric oxygen therapy for interstitial cystitis resistant to conventional treatments

Tomoaki Tanaka¹, Hidenori Kawashima¹, Tetsuya Makino¹, Sadanori Kamikawa³, Noboru Kato² and Tatsuya Nakatani¹

¹Department of Urology, ²Critical Care Medicine, Osaka City University Graduate School of Medicine, and ³Department of Urology, Osaka City General Hospital, Osaka, Japan

Abstract: We treated two cases of interstitial cystitis (IC) that were resistant to some conventional therapies with hyperbaric oxygen (HBO). Both patients underwent 20 sessions of 100% oxygen inhalation (2.0 atmosphere absolute for 60 min/day × 5 days/week for 4 weeks) in a hyperbaric chamber. The period of follow up was 12 months for case 1 and 9 months for case 2. After a course of HBO, the bladder mucosal ulcer (Hunner’s ulcer) disappeared, and changes from baseline in pain and urinary frequency was constitutively inhibited. There were no adverse events during the 20 treatment sessions. One woman (case 1) had mild Eustachian tube dysfunction, resulting in a transient hearing impairment. HBO seems to be an option for treatment of IC resistant to conventional therapies.

Key words: Hunner’s ulcer, hyperbaric oxygen, interstitial cystitis, visual analog scale.

Introduction

Interstitial cystitis (IC) is a collective term, including a variety of clinical findings. In view of definite symptoms, the term ‘painful bladder syndrome’ is more adequate. Only 10–50% of IC patients demonstrate a classical mucosal ulcer (Hunner’s ulcer) and most of them are diagnosed as the result of some positive factors and exclusions.¹² Regrettably, the etiology of IC remains unclear. Many options for the treatment of IC have been proposed, while the suitable therapy has yet to be defined from clinical evidence.³–⁵ Hyperbaric oxygen (HBO) therapy has been used mainly on the patients with hemorrhagic cystitis or radiation cystitis and has gained recognition during the last 15 years.⁶–⁹ Especially, chronic radiation cystitis sensitive to HBO is almost equivalent to IC regarding clinical conditions and histological alterations. In those bladder diseases, there are both ischemia and a reduction in bladder capacity due to fibrosis of the bladder wall.¹⁰–¹² Thus, we have planned and conducted a pilot study of HBO in two IC patients. We got the approval from the ethics committee of our institute and the informed consent from the patients before starting HBO therapy.

Case report

Case 1

A 79-year-old woman with IC had undergone hydrodistension (80 cmH₂O) three times at our department since she had been diagnosed with IC in January 2004. After the first hydrodistension, the intravesical instillation of heparin (10,000 IU × 2 times/week for 15 weeks) was added. Transient palliation of urgency, urinary frequency and pelvic pain was seen, but the duration of effectiveness was decreased as repeating hydrodistension. The cystoscopic examination revealed a Hunner’s ulcer and severe glomerulations on a distended bladder mucosa. We treated the patient with HBO (2.0 atmosphere absolute [ATA] for 60 min/day × 5 days/week for 4 weeks) immediately after the fourth hydrodistension in December, 2004. HBO treatment achieves a decrease of urinary frequency and pelvic pain. The daily voiding frequency decreased from a baseline range of 25 to a range of 8, 9 and 9 times per day at 1, 3 and 9 months follow up, respectively (Table 1). The patient reported an improvement on the pain scale from the baseline of 100 mm to a range of 30, 35 and 40 mm at 1, 3 and 9 months follow up, respectively (Table 1). Initially, a baseline range of functional bladder capacity was 30 mL. HBO therapy resulted in a bladder capacity ranging 100–150 mL at 1, 3 and 9 months follow up (Table 1). Furthermore, HBO treatment achieved a significant amelioration of both glomerulations and Hunner’s ulcer on endoscopic findings (Fig. 1a,b). The patient had mild Eustachian tube dysfunction during HBO treatment, resulting in a transient hearing impairment. Conservative medication was required for this condition. At 12 months after HBO treatment, the remission of symptoms appeared (Table 1). We are proposing a second HBO or other options for IC.

Case 2

A 61-year-old woman was diagnosed with IC at another hospital in January, 2005. Simultaneously, the patient underwent hydrodistension and laser ablation for mucosal ulcer, but symptoms were not improved. Then, other conventional treatments (e.g. intravesical instillation of heparin, non-steroidal anti-inflammatory drugs [NSAIDs] and IPD) were not effective for this patient’s condition. In particular, the patient was treated with the continuous epidural analgesia against extreme pelvic pain associated with bladder filling. On endoscopic findings, there were moderate glomerulations and a Hunner’s ulcer on bladder mucosa. We treated with HBO treatment under the same conditions as case 1 in April 2005. HBO treatment resulted in a decrease of urinary frequency and pelvic pain. Furthermore, the range of functional bladder capacity was increased from 80 mL before treatment to 150 mL at 1 month follow up. Those changes in symptoms from baseline have been sustained for 8 months (Table 1).
The biological mechanism of HBO originated from hypersaturating oxygen dissolved in plasma due to treatment. This phenomenon results in an increased diffusion gradient between the circulation and surrounding tissues, forcing oxygen into the damaged hypoxic urothelial tissues. Subsequently, HBO treatment stimulates leukocyte function characterized by phagocytosis, producing growth factors that enhance angiogenesis. Finally, healthy granulation tissue grows at the local sites.

HBO therapy has been mainly available for chronic radiation cystitis and hemorrhage cystitis since 15 years ago. In particular, chronic radiation cystitis represents some histological alterations including submucosal hemorrhage, interstitial fibrosis and smooth muscle fibrosis, which correspond to IC. According to those findings, we postulated that HBO could be an effective option for IC with typical cystoscopic findings (glomerulations, Hunner’s ulcer and interstitial fibrosis). The two cases we treated with HBO showed a significant decrease of urinary frequency and pelvic pain, along with an increase of bladder capacity. Furthermore, the effects in symptoms have been sustained for several months. Recently, van Ophoven A et al. has reported a pilot study of HBO for six IC patients. They suggested that there was no difference between the classical type and the non-ulcerative type of IC regarding effectiveness of HBO. A larger, randomized clinical trial will be needed to define criteria of HBO for IC patients. HBO therapy is well tolerated. Adverse events, including visual disturbance, Eustachian tube dysfunction and claustrophobia are unusual. Furthermore, the advantage of HBO is non-invasive nature compared with hydrodistension or intravesical instillation of dimethylsulfoxide (DMSO).

The present two cases suggest that HBO could be used for treatment of IC patients resistant to conventional therapies.

### Discussion

The biological mechanism of HBO originated from hypersaturating oxygen dissolved in plasma due to treatment. This phenomenon results in an increased diffusion gradient between the circulation and surrounding tissues, forcing oxygen into the damaged hypoxic urothelial tissues. Subsequently, HBO treatment stimulates leukocyte function characterized by phagocytosis, producing growth factors that enhance angiogenesis. Finally, healthy granulation tissue grows at the local sites.

HBO therapy has been mainly available for chronic radiation cystitis and hemorrhage cystitis since 15 years ago. In particular, chronic radiation cystitis represents some histological alterations including submucosal hemorrhage, interstitial fibrosis and smooth muscle fibrosis, which correspond to IC. According to those findings, we postulated that HBO could be an effective option for IC with typical cystoscopic findings (glomerulations, Hunner’s ulcer and interstitial fibrosis). The two cases we treated with HBO showed a significant decrease of urinary frequency and pelvic pain, along with an increase of bladder capacity. Furthermore, the effects in symptoms have been sustained for several months. Recently, van Ophoven A et al. has reported a pilot study of HBO for six IC patients. They suggested that there was no difference between the classical type and the non-ulcerative type of IC regarding effectiveness of HBO. A larger, randomized clinical trial will be needed to define criteria of HBO for IC patients. HBO therapy is well tolerated. Adverse events, including visual disturbance, Eustachian tube dysfunction and claustrophobia are unusual. Furthermore, the advantage of HBO is non-invasive nature compared with hydrodistension or intravesical instillation of dimethylsulfoxide (DMSO).

The present two cases suggest that HBO could be used for treatment of IC patients resistant to conventional therapies.

### References

5 Peeker R, Fall M. Interstitial cystitis – a time for revision of name and diagnostic criteria in the new millennium? BJU Int. 2002; 89: 637–8.
Copyright of International Journal of Urology is the property of Blackwell Publishing Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.